MKS Instruments

Phase A — Understand the business

Company Overview

MKS is the broadest critical-subsystem supplier to the wafer-fabrication-equipment (WFE) ecosystem — the company's own framing is "Surround the Wafer®," and it claims to address over 85% of the WFE market by content. It does not build the etch/deposition tools themselves (that's Applied Materials, Lam, Tokyo Electron); it sells the guts those tools are built from — vacuum pressure/flow control, gas and reactive-gas delivery, RF/microwave power generation, lasers, optics, precision motion, and (since Atotech) the wet-process chemistry and plating used downstream in advanced packaging. It is, structurally, a picks-and-shovels supplier to the picks-and-shovels makers — a toll on the toolmakers.

Three reportable divisions:

• Vacuum Solutions (VSD) — $1,579M revenue. Pressure & vacuum control, materials delivery (flow/valves), power solutions (RF/microwave), plasma & reactive-gas. The legacy MKS core; most levered to semi capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs..
• Photonics Solutions (PSD) — $1,029M revenue. Lasers, optics, motion control, vibration isolation, and laser-drilling systems for PCB/HDI/package-substrate (the Newport + ESI heritage).
• Materials Solutions (MSD) — $1,323M revenue. The Atotech chemistry/plating business — consumable chemistries + plating equipment for PCBs, package substrates, wafer-level packaging, plus decorative/functional surface finishing. This is the highest-margin segment (~56% gross margin) and the recurring-consumables story.

Three end-markets (cross-cut the divisions): Semiconductor $1,696M (43%), Electronics & Packaging $1,111M (28%), Specialty Industrial $1,124M (29%).

Customers: thousands worldwide; top-10 = 35% of revenue (up from 32% in 2024, 30% in 2023); no single customer >10% of revenue in any of 2025/2024/2023. The large customers are concentrated in semiconductors — i.e. AMAT, Lam, TEL and the device makers (TSMC/Samsung/SK Hynix/Intel). Applied Materials publicly flagged a $250M supply-chain hit from MKS's 2023 ransomware outage — direct confirmation that MKS is an embedded, hard-to-substitute AMAT supplier.

Payment terms: mostly point-in-time revenue on shipment, net 30–60 days; plating equipment (MSD) recognized over time (cost-to-cost) with lead times up to 12 months; service/extended-warranty recognized ratably. ~12.6% of revenue is service (recurring-ish); the MSD chemistry consumable stream is the real recurring-revenue thesis but isn't broken out as a clean ARR figure.

Supply Chain

Upstream → MKS → end customer, named where the filing names them:

• Inputs MKS buys: electronic, optical, mechanical and electrical components (some custom-designed to spec); for MSD chemistry — substances, metals and specialty compounds bought from a global base, "from commodities in bulk to small quantities of specialty compounds". Sole/limited-source dependencies exist for "certain metals and electronic components," some forced by customers' "copy exact" qualification rules — a genuine single-source chokepoint MKS itself flags as a risk.
• MKS manufacturing footprint: 18+ countries — Austria, Brazil, Canada, China, France, Germany, India, Israel, Italy, Japan, Malaysia, Mexico, Romania, Singapore, Slovenia, South Korea, Taiwan, US — plus new fabs being built in Thailand and fitted out in Malaysia (Asia-shifting the footprint; long-lived assets outside the US rose to 70% of total in 2025 from 59%). Relies on subcontracted ops in Mexico and contract manufacturers in Asia.
• Downstream chokepoint — MKS is the chokepoint: because MKS content sits inside almost every deposition/etch/clean/litho/metrology tool, an MKS outage cascades through the whole fab-tool supply chain. The 2023 ransomware event is the proof: ~$200M of MKS sales vanished in one quarter and AMAT took a $250M downstream hit.
• End buyers: WFE OEMs (Applied Materials, Lam Research, Tokyo Electron, ASML, KLA) → who ship to device makers (TSMC, Samsung, SK Hynix, Intel, Micron); plus PCB/package-substrate makers and specialty-industrial OEMs directly for MSD/PSD.

Geographic chokepoint: 81% of revenue is international, with China the single largest country and South Korea/Singapore/Taiwan/Japan close behind. China grew +$155M in 2025 — a tailwind that doubles as the largest geopolitical risk (see Lens 13).

Competitive Advantages (moats)

Moat 1 — breadth + "copy-exact" lock-in (the real one). Once an MKS subsystem is designed into a customer's qualified process tool, "copy-exact" rules make it extremely costly to swap — re-qualification can take quarters and risk yield. No competitor "competes across all product lines"; MKS is the only one selling the full Surround-the-Wafer stack. That breadth is the durable edge: a fab buying MKS for pressure control, RF power, and reactive-gas has high switching friction across all three.

Moat 2 — IP + process know-how. 585 US patents + 2,217 foreign patents (expiring through 2044), 150 pending US applications, 15 MSD technology centers. Decades of vacuum/plasma/RF domain expertise that is hard to replicate.

Moat 3 — recurring chemistry consumables (Atotech thesis). MSD's plating chemistries are consumed per-wafer/per-board, giving a razor-blade annuity tied to production volume (not just capex cycles) — the strategic rationale for the $5B+ Atotech deal: smooth the notoriously cyclical equipment revenue with a consumables stream at the Interconnect.

Bargaining power — asymmetric. Over customers: moderate-to-strong on the embedded subsystems (copy-exact), weaker where competitors exist niche-by-niche. Over suppliers: weakened by sole-source inputs and copy-exact constraints that prevent dual-sourcing. Net: the moat is real but narrower than a monopolist's — MKS faces named competition in every product line (Lens 13), just never one competitor across all of them.

Where the moat is thin: PSD's lithography/metrology/inspection products lost share in 2025 (sales fell) — the photonics franchise is the most contested, least defensible leg.

Segments

By division:

*FY2025 segment GP% read from the segment reconciliation table; division-level GP% moved <1pt vs FY2024 — the structure (MSD ~56%, VSD ~43%, PSD ~45%) is stable.

By end-market:

Trend read: the two accelerating legs (Semi +13%, E&P +20%) are both AI/advanced-packaging-driven — VSD into logic/foundry capex, MSD/PSD into the package-substrate and HDI build-out for AI accelerators. Specialty Industrial is the decelerating ballast (−4%), dragging on the blend. Geography: international rose to 81% (from 78%), China +$155M. Three-year revenue arc: $3,622M (2023) → $3,586M (2024) → $3,931M (2025) — i.e. MKS only just cleared its 2023 level in 2025; this is a company emerging from a two-year semi-capex trough, not one compounding from strength.

---

Phase B — Measure performance

Earnings Result (latest print: Q1 2026, reported 2026-05-07)

The print:

• Revenue $1,078M, +15.2% YoY (vs $936M Q1'25), +4% sequential. Modest top-line beat vs ~$1.07B consensus.
• GAAP gross profit $507M → GAAP GM 47.0%; income from operations $149M (13.8% margin, up from 11.9%).
• GAAP net income $84M, GAAP diluted EPS $1.18 (vs $0.77). Non-GAAP EPS $2.30 vs $2.04 est (+12.75%), up from $1.71 YoY. The ~$1.12 GAAP→non-GAAP bridge is dominated by the $63M/qtr intangible amortization from acquisitions.
• Adjusted EBITDA $277M, 25.7% margin (+50bps YoY), above guidance high end, up from $236M.

What drove it: Semiconductor revenue $466M (+13% YoY, +7% QoQ) — plasma/vacuum/RF power for deposition & etch surged on AI capacity; Electronics & Packaging $321M (+6% QoQ); the residual ~$291M Specialty Industrial. Management explicitly credited AI-related demand.

Guidance/outlook: management guided revenue toward ~$1.08B (next Q) and ~$1.14B further out — sequential acceleration, AI tone unmistakably positive at JPMorgan.

Balance-sheet flags:

• Cash $569M (down from $675M) — used to part-fund the Feb-2026 debt prepayment.
• Receivables jumped to $775M from $651M (+$124M) — a build that outran the +15% revenue growth; AR up ~19% QoQ vs revenue +4% QoQ. Worth watching, though Q1 AR builds are seasonal for MKS and DSO is not yet alarming.
• Inventory $949M (up $28M).
• Operating cash flow only $53M in Q1 (vs $141M Q1'25) — the AR build and a $68M accrued-comp paydown drained it; this is a working-capital dip, not an earnings problem.
• Debt optics distorted by reclass: short-term debt shows $1,398M (from $51M) and long-term $2,650M (from $4,150M) — that's the Feb-2026 refinancing reclassification, not new borrowing. Total debt ~$4.05B, roughly flat.

Market reaction: stock +~10% premarket on the print — the market rewarded the AI-demand beat and EBITDA guide-beat. Read: expectations were already high and MKS cleared them.

Unusual vs own history: the $18M "fees and expenses related to debt activities" + $5M extinguishment loss in Q1 are refinancing one-offs; a $3M legal settlement appeared. None structural.

Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty) — this lens is -grounded and shallower than ideal; flag for the next refresh to ingest Q1'26 + the prior 3 quarters.

Trajectory (from web summaries):

• 2023 (ransomware year): crisis-management tone — "global operations restored," recovery framing, Atotech "excellent progress integrating".
• 2024–2025: deleveraging discipline becomes the drumbeat — repeated voluntary $100M term-loan prepayments, "resilient global manufacturing and supply chain" language around tariffs.
• Q1 2026: decisively bullish on AI — "AI demand drives beat, strong outlook"; at JPMorgan management said things that "may change how investors see the stock".

Recurring phrases: "Surround the Wafer," "Optimize the Interconnect," "foundational technology," "broadest critical subsystem provider." What they stopped saying: the 2023 ransomware/recovery framing has fully dropped out; the narrative has rotated from crisis + integration → deleveraging → AI growth. Tone is at a multi-year high — which is itself a mild contrarian caution.

Comps

Peer set: semiconductor subsystem/materials suppliers + the WFE OEMs MKS sells into.

MKSI multiple derivation: price ~$388–410 × non-GAAP FY2026 EPS consensus ~$10.00 → fwd P/E ≈ 39x (range 35–41x across the price band). On trailing GAAP EPS $4.39 → ~89x (not the right lens given the amortization drag). EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap. ≈ $26.5B equity + $4.05B debt − $0.57B cash ≈ $30.0B; on FY2026E adj. EBITDA ~$1.15B → EV/EBITDA ≈ 13x.

Read: MKSI's ~39x forward non-GAAP P/E sits below AMAT (~47x) and Lam (~50x) and above the ~33x industry average. The discount to the OEMs is rational — MKS carries $4B of leverage and the Atotech overhang, and its growth is a derivative of the OEMs' growth. The premium to the industry reflects the AI cycle. It is not cheap on any absolute measure; it is cheap only relative to the toolmakers it supplies.

Stock-Price Catalysts (>5% moves, last ~5yr)

Mostly; pattern-reading is.

• Jul 2021 — Atotech deal announced (~$5.1B incl. debt). The transformational, debt-loading event; defined the next 5 years.
• Feb 2023 — ransomware disclosure. ~$200M sales hit guided; stock initially wobbled but rose ~5% after the Feb-28 call reassured on recovery. Lesson: the market forgave a one-off operational shock once recovery was credible.
• 2023 — $1,902M goodwill/intangible impairment → GAAP net loss $(1,841)M, EPS $(27.54). The Atotech writedown — the scar that still depresses GAAP optics.
• 2024–2025 — deleveraging re-rating. Each $100M voluntary prepayment + the May-2024 $1.4B convert + the Feb-2026 refinancing chipped at the risk premium; the stock roughly tripled off its 2023 lows (April 2026 print shows ~$269 → ~$390+ by late June 2026 ).
• May 2026 — Q1 beat, +~10% on AI demand.

What the market actually reacts to for MKSI: (1) the WFE/semi-capex cycle (the dominant beta — MKS is a high-beta WFE play), (2) balance-sheet/deleveraging milestones (idiosyncratic, the 2023–2026 re-rating story), and (3) AI-capacity headlines. It reacts less to any single customer (no >10% concentration) and more to the aggregate capex tape. This is a cyclical + balance-sheet stock, now trading as an AI-capex stock.

---

Phase C — Judge people & books

Management

• CEO — John T.C. Lee. CEO since 2018; PhD physicist, long internal tenure (prior COO/President), photonics-rooted. Track record: drove the Atotech acquisition (2022) — the defining strategic bet — and the subsequent integration + aggressive deleveraging. Steered the company through the 2023 ransomware crisis with operations restored within months and the year largely recouped. Capital-allocation read: mixed-to-improving. Atotech loaded $4B+ of debt and produced a $1.9B impairment 18 months in (a value-destruction mark), but the post-2023 execution — four $100M voluntary prepayments in 2025, the $1.4B low-coupon convert (1.25%), and the Feb-2026 refi cutting ~$27M/yr of interest — is textbook disciplined deleveraging. The thesis that consumables would smooth the cycle is now being tested favorably as MSD compounds at ~12% with ~56% margins.
• CFO — Ramakumar (Ram) Mayampurath. EVP & CFO; architect of the deleveraging/refinancing program.
• Chairman — Gerald G. Colella (former MKS CEO) — founder-adjacent continuity on the board.
• CAO — Michelle M. McCarthy.
• Skin in the game / insider ownership: our figures not on shelf — n/a for precise insider %. Comp is RSU-heavy with performance-based Adjusted-EBITDA RSUs (0–200%) and 3-yr relative-TSR RSUs — incentive design is reasonably aligned to operating performance and shareholder return. No 10b5-1Rule 10b5-1 planA schedule an insider sets in advance saying when their shares will be sold, so the sales cannot be timed on private news. A sale made OUTSIDE such a plan is a live decision, which is why it carries more information. adoptions/terminations by directors/officers in Q4 2025.
• Red flags: none promotional. The honest knock is the Atotech price — paid a full multiple at a cycle-ish peak, took a fast $1.9B impairment, and spent three years digging out of the leverage. Archetype: professional manager / operator-technologist, not founder. For a cyclical capital-intensive supplier emerging from a debt-funded mega-deal, disciplined-operator is exactly the archetype you want — and is what the 2024–2026 record shows.

Forensic Red Flags

Forensic lens. Every figure labeled.

Income statement:

• GAAP vs non-GAAP gap is large and structural. $247M/yr intangible amortization is the bulk of the ~$5.60/yr GAAP→non-GAAP EPS bridge. It is a real acquisition cost (Atotech/Newport/ESI), not SBC games — but it means the 89x trailing GAAP P/E is misleading high and the 39x non-GAAP is the fair lens. Investors must not anchor on GAAP here.
• SBC modest: $55M FY2025 (~1.4% of revenue) — low for a tech name; non-GAAP is not heavily flattered by SBC add-back.
• Tax-rate noise: effective rate 2.9% (2025) vs (5.7)% (2024) — driven by a $72M valuation-allowance release in 2025 on foreign NOLs/interest carryforwards. A one-time GAAP-EPS flatterer; normalize for it in forward years.

Balance sheet:

• Goodwill $2,565M + intangibles $2,065M = $4.63B = 53% of total assets ($8.73B). Heavy. Already impaired once ($1.9B in 2023). Annual Oct-31 test passed qualitatively in 2025 & 2024; a WFE downturn that cuts the MSD/PSD cash-flow forecasts is the most plausible future impairment trigger — and MKS's own stock price/control premium feeds the test.
• Receivables build (Q1'26): +$124M QoQ on +4% sequential revenue — flagged in Lens 5; monitor for a DSO trend, not yet a red flag.
• Excess/obsolete inventory charges: $45M (2025), $56M (2024), $64M (2023) — elevated but declining, consistent with a recovering demand environment.

Cash flow:

• FY2025 quality looks clean: OCF $645M vs net income $295M; the gap is $344M D&A less a $196M deferred-tax swing — earnings are well cash-backed. FCF ≈ $497M (OCF $645M − capex $148M). The Q1'26 OCF dip ($53M) is working-capital timing, not deterioration.

Leverage (the headline risk):

• Total debt ~$4.05B; net debt ~$3.48B. Net-debt/FY2025-adj-EBITDA ≈ 3.0–3.2x. Down hard from post-Atotech ~5x+ but still a levered balance sheet for a cyclical. Term-loan rate 5.4% weighted; ~66% swapped to fixed.

Audit/controls: PwC, auditor since 1981; clean opinion + effective ICFR for FY2025; single critical audit matter = revenue recognition (routine for this model); no changes/disagreements with accountants. No restatements.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None naming MKS, 2021-06-29 → 2026-06-29, per SEC EDGAR EFTS.
• AAERs: None in the same window, per EDGAR EFTS.
• 10-K Item 3 (Legal Proceedings): "subject to various legal proceedings and claims that have arisen in the ordinary course of business… in the opinion of management, the ultimate disposition…will not have a material adverse effect" — no material litigation disclosed. A $3M legal settlement ran through Q1'26 opex — immaterial.
• Non-SEC enforcement (web): no material FTC/DOJ/FDA/CFPB enforcement actions surfaced. The relevant exposure is trade-compliance / export-control (EAR, ITAR) given the China footprint — a regulatory-risk, not a finding. The Feb-2023 ransomware event triggered consumer data-breach notifications (employee/personal data) but no regulatory penalty surfaced.
• Net: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-29. The forensic risk here is balance-sheet (goodwill + leverage), not accounting integrity.

---

Phase D — Project & stress-test

Forward Projection (FY2026 / FY2027 / FY2028, non-GAAP EPS)

Built bottom-up from Q1 2026 actuals + guidance. No our model create (watchlist mode). Every input labeled; outputs.

Anchors: Q1'26 revenue $1,078M, adj. EBITDA $277M (25.7%), non-GAAP EPS $2.30. Guidance points to sequential acceleration (~$1.08B → ~$1.14B). ~71M diluted shares (incl. convert dilutionDilutionIssuing new shares, so each existing share owns a smaller slice of the same company.). WFE backdrop: +9% (WFE) to +18% (300mm) in 2026, +7–14% in 2027.

• Bull: WFE runs hotter (300mm +18%/+14%), China stays open, MSD consumables inflect → FY2026 ~$10.75, FY2027 ~$13.50, FY2028 ~$15.00.
• Bear: WFE rolls over / China export-control shock / tariff margin hit → FY2026 ~$8.75, FY2027 ~$8.50 (a cycle-down year), FY2028 ~$9.50. In a true WFE downturn, this de-rates and the goodwill test bites.

Base call (for tracking, not logged): MKSI FY2026 non-GAAP EPS ≥ $10.00, ~60% probability — in line with consensus, slight upside skew given Q1 momentum, but tariff/China is a real two-sided tail. (Resolves ~2027-02 with the FY2026 10-K.)

Bull vs Bear

Bull case. MKS is the indispensable, broadest content supplier to a WFE cycle entering a multi-year AI/HBM/advanced-packaging up-leg (record $156B equipment sales projected by 2027 ). It addresses >85% of WFE with copy-exact lock-in, so it captures the up-cycle with operating leverage and now carries a higher-margin recurring chemistry annuity (MSD ~56% GM) that dampens the trough. The 2024–2026 deleveraging has de-risked the balance sheet (net leverage ~3x and falling, ~$27M/yr fresh interest savings), so each turn of the cycle now converts to EPS faster than the last — earnings + multiple can compound together. At ~39x forward it trades at a discount to the AMAT/Lam tools it sells into, despite arguably better cyclical-trough protection via consumables.

Bear case (permanent-impairment risks). (1) It's a derivative cyclical at a cycle-high multiple — ~39x forward non-GAAP and ~2x the median analyst target means a lot of the AI up-cycle is already priced; a WFE air-pocket (China digestion, memory wobble) takes both EPS and the multiple down. (2) $4.63B goodwill+intangibles (53% of assets) already impaired once — a demand cut that lowers MSD/PSD forecasts triggers another writedown and a GAAP-loss headline. (3) China concentration meets a hardening export-control / 25%-tariff regime — the single largest country is also the single largest policy risk, and it grew +$155M in 2025 (so the at-risk base is rising).

Pre-mortem (18 months out, thesis broke). WFE 2027 came in flat-to-down as China front-loaded buying into 2025–26 and then digested; memory capex paused; a new BIS rule or retaliatory tariff cut MKS's China shipments 15–20%. Revenue stalled near $4.4B, non-GAAP EPS slipped toward $8.50, the multiple compressed from ~39x to ~22x, and the stock halved from ~$390 to ~$200 (back toward the bear-target band). The Oct-2027 goodwill test forced a partial MSD impairment, putting a GAAP loss in the headline.

Are multiples too high? For a derivative cyclical, yes — uncomfortably. ~39x forward is a secular-growth multiple on a cyclical earnings stream that only just exceeded its 2023 revenue. The bull needs the AI cycle to be durable and MSD consumables to genuinely re-rate MKS toward a less-cyclical multiple. That can happen — but you're paying for it now.

Contrarian view (what the market refuses to see). Two-sided. The bullish contrarian: the consumables annuity is structurally de-cyclicalizing MKS and the market is still pricing it as a pure WFE beta — the re-rate is real and unfinished. The bearish contrarian (which I weight higher at this price): the market is extrapolating a China-front-loaded, AI-front-loaded 2025–26 capex surge as a clean secular trend, and is under-pricing the digestion air-pocket + export-control tail that historically follows every WFE spike — on a balance sheet still carrying $4B of debt.

Devil's Advocate (short-seller)

Skeptical short dismantling the bull.

• What structurally breaks the model: a WFE down-cycle. MKS's revenue is a high-beta derivative of semi-capex; it has no control over the cycle's timing. The 2023→2024 revenue decline ($3,622M → $3,586M) shows the downside is real and recent.
• Revenue concentration & shift: not customer-concentrated (no >10%), but end-market + geographic concentrated — 43% semi, China the #1 country. If China WFE normalizes after a policy-driven front-load, or a BIS rule cuts shipments, the at-risk base ($1.7B semi, China-heavy) is large and growing (+$155M China in 2025).
• Why the moat is weaker than bulls think: MKS faces named competitors in every single product line — VSD: Advanced Energy, Inficon, Hitachi, Horiba, Brooks, VAT; PSD: Trumpf, Lumentum, IPG, Coherent, Excelitas, Jenoptik, Thorlabs, Via Mechanics, Mitsubishi; MSD: Element Solutions, Qnity, Uyemura, JCU, Okuno, Schmid. The "no one competes across all lines" defense is real for breadth, but line-by-line, MKS is contestable — and PSD already lost litho/metrology/inspection share in 2025.
• Most dangerous underestimated competitor: Advanced Energy (AEIS) in RF/plasma power — a focused subsystem peer attacking VSD's most profitable, most cyclical content, trading at its own rich multiple (EV/EBITDA peaked ~45x ) i.e. funded to compete.
• Worst capital-allocation move: the Atotech price. A ~$5B debt-funded deal near a cycle peak that produced a $1.9B impairment within ~18 months and a multi-year deleveraging slog. The thesis may yet pay off, but the entry destroyed measurable value and constrained the company through 2023–2026.
• What must hold for today's price: WFE up-cycle persists through 2027–28 and margins expand and China stays open and the consumables story earns a multiple re-rate. That's a lot of "ands" at ~39x.
• If growth disappoints 20–30%: FY2027 revenue ~$3.8–4.0B instead of ~$4.85B; non-GAAP EPS toward ~$8 or below; multiple compresses to low-20s; stock roughly halves and a goodwill impairment becomes likely.
• Single scenario that permanently impairs: a structural China decoupling (export controls that wall MKS out of its largest market) coinciding with a memory-capex pause — a demand shock big enough to force a large MSD/PSD goodwill writedown and a covenant-uncomfortable leverage spike. Plausibility: moderate (policy direction is hardening, but MKS's content is broad and partly localized via the Asia footprint).

Management Questions (ordered by information value)

1. What is MSD's recurring consumable-chemistry revenue as a % of total, and its growth/margin through the last WFE trough — i.e. how much does it actually de-cyclicalize the company? (The entire re-rating thesis hinges on this single answer.)
2. What share of revenue is shipped to / consumed in China, and what is the realistic downside if export controls tighten another notch or 25% semiconductor tariffs persist?
3. How much of 2025–26 China/semi demand is genuine new capacity vs. front-loading ahead of tariffs/controls — what's your read on the 2027 digestion risk?
4. Net-leverage target and timeline — where do you stop deleveraging and redeploy FCF (buybacks, M&A, dividend growth)?
5. What's the goodwill/intangible headroom by reporting unit — at what revenue/margin decline does the Oct-31 test fail again?
6. Where are you gaining vs losing design-in share by product line — specifically, what's the plan for PSD litho/metrology/inspection after the 2025 share loss?
7. How exposed is the sole/limited-source + copy-exact input base to disruption, and what's the dual-sourcing roadmap post-2023?
8. What is the incremental operating leverage (drop-through) on the next $1B of revenue, by division?
9. Post-ransomware, what's the current cybersecurity posture, and could a repeat still take ~$200M out of a quarter?
10. How do tariffs flow through gross margin in 2026, and how much can the Asia manufacturing build-out (Thailand/Malaysia) mitigate it?
11. What's the M&A appetite now that leverage is down — would you do another Atotech-scale deal, and what did you learn from the price you paid?
12. What's the capital-intensity trajectory (capex/sales) as you build Thailand/Malaysia, and the AMIC/CHIPS-credit benefit?
13. How should we think about VSD's beta to logic/foundry vs memory capex specifically?
14. What would make you walk away from the consumables-re-rate narrative — what disconfirms it?
15. Convertible Notes mature 2030 at a ~$154 conversion price (well in-the-money at ~$390) — what's the dilution/refinance plan, and does the capped call ($237 cap) fully cover it?

---